blastic plasmacytoid dendritic cell neoplasm
Haematology · 2023–2023
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tagraxofusp First-line treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in patients who have not received prior systemic therapy. | Jul 2023 | Not recommended | input received Rare Cancers Australia |
Who spoke
Rare Cancers Australia
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 0 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| tagraxofuspTagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) | TA782 | terminated | 2022-03 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.